论文部分内容阅读
用错配引物聚合酶链反应结合限制性片段长度多态性分析（ｍｐＰＣＲ－ＲＦＬＰ）对１５例血清ＨＢｅＡｇ阳性、ＨＢＶ－ＤＮＡ斑点杂交阳性的慢性乙型肝炎患者进行了干扰素疗法与ＨＢＶ前Ｃ区基因１８９６位点突变之间关系的观察。结果显示，治疗前后ＨＢＶ野生株（Ｗ）和突变株（Ｍ）的变化有四种类型，即Ｗ→Ｗ（８例）；Ｗ＋Ｍ→Ｗ＋Ｍ（３例）；Ｗ→Ｗ＋Ｍ（３例）；Ｗ＋Ｍ→Ｗ（１例）。以ＨＢｅＡｇ阴转率和ＨＢＶ－ＤＮＡ阴转率为指标分析干扰素疗效，ＨＢＶ野生株感染组和野生株与突变株混合感染组之间无显著性差异（Ｐ＞０．０５）。结论：干扰素治疗后部分患者可发生ＨＢＶ前Ｃ区基因点突变。该突变株的存在似不影响干扰素的疗效。
Fifteen patients with chronic hepatitis B who had positive serum HBeAg and HBV-DNA positive dot blot hybridization were treated with interferon-α (HBV) and HBV pre-C (superscript C) by using mismatch primer polymerase chain reaction and restriction fragment length polymorphism analysis (mpPCR-RFLP) Observation of the relationship between the 1896 locus mutation and the gene mutation. The results showed that there were four types of changes in HBV wild-type (W) and mutant (M) before and after treatment: W → W (8 cases); W + M → W + M (3 cases); W → W + M → W (1 case). The effect of interferon on HBeAg negative rate and HBV-DNA negative rate was analyzed. There was no significant difference (P> 0.05) between the HBV wild-type infection group and the wild-type and mutant mixed infection group. Conclusions: Pre-HBV precore mutation may occur in some patients after interferon treatment. The presence of the mutant does not appear to affect the efficacy of interferon.